AC Immune SA (ACIU) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
AC Immune SA (ACIU) has outperformed Pyxis Oncology (PYXS) over the past year, losing 28.2% versus a loss of 47.0%. Over five years, ACIU leads with a -59.5% price change compared with -82.8% for PYXS. AC Immune SA is the larger company by market cap ($248.6 million vs $242.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | PYXS |
|---|---|---|
| Share price | $2.50 | $2.03 |
| Market cap | $248.57M | $242.50M |
| 1-day change | -1.96% | +2.01% |
| YTD return | -20.38% | +76.52% |
| 1-year return | -28.16% | -47.00% |
| 5-year return | -59.55% | -82.75% |
| Forward P/E | 4.20 | — |
| EPS (TTM) | $-0.54 | $-1.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $5.55 |
| 52-week low | $2.10 | $1.03 |
| Distance from 52-week high | -37.50% | -63.42% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +240.80% | +327.09% |
| Average volume | 201.86K | 1.26M |
| Shares outstanding | 99.43M | 119.46M |
| Employees | 90 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACIU has outperformed PYXS by 18.8 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
ACIU vs PYXS FAQ
Which is bigger, AC Immune SA or Pyxis Oncology?
AC Immune SA (ACIU) is larger, with a market capitalization of $248.57M compared with $242.50M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, ACIU or PYXS?
ACIU returned -28.16% over the past 12 months, compared with -47.00% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.